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Method
The present report primarily studied the effects of geniposide on cognitive dysfunction in a double-transgenic AD mouse model (APP/PS1) on early and late stages. Male APP/PS1 mice aged 6 month and 12 month were given water, geniposide (25mg.kg -1 ) once a day by oral gavage, and age-matched C57BL/6 mice were treated with water and geniposide (25mg.kg -1 ). Aricept (0.75mg.kg -1 ) was used in the positive control group. Morris water maze performance was assessed after 3 months of treatment.
Result
The APP/PS1 mice had longer escape latency and lower percentage of activities in platform quadrant than the C57BL/6 mice (p<0.05) both in the early-and late-stage treatment. In addition, geniposide significantly improved learning deficits as well as Aricept, compared with vehicle control treatment (p<0.05).
Conclusion
Geniposide can improve cognitive function of the double transgenic mouse model at early and late-stage of Alzheimer's disease, with a possible mechanism related with neuroprotective and anti-inflammatory activities.
The study suggested that oral supplementation of geniposide might be a potential therapeutic strategy for the treatment of early-and late-stage of Alzheimer's disease. 
